Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 2/20 | 0.43 |
| ▸ | MIF | P14174 | 1/20 | 0.41 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 4/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 4/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | MAPKAPK2 | P49137 | 2/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6615348 | 0.80 | CYP1A2 (0.48) | CYP1A2CYP2C9P2RX7HTTADORA3 | |
| SCHEMBL16202001 | 0.80 | CYP1A2 (0.48) | CYP1A2CYP2C9P2RX7HTTADORA3 | |
| SCHEMBL10361314 | 0.79 | ALDH1A1 (0.43) | HTTMAPTSMN1; SMN2TP53POLB | |
| SCHEMBL22897465 | 0.79 | CYP1A2 (0.47) | CYP1A2CYP2C9P2RX7HTTADORA3 | |
| SCHEMBL4548444 | 0.78 | P2RX7 (0.51) | CYP1A2CYP2C9P2RX7HTTMIF | |
| SCHEMBL10360384 | 0.78 | RXRA (0.42) | MAPTSMN1; SMN2TP53POLBPTGS2 | |
| SCHEMBL31301332 | 0.77 | MAPT (0.55) | CYP1A2CYP2C9MAPTSMN1; SMN2TP53 | |
| SCHEMBL6614645 | 0.76 | CYP1A2 (0.44) | CYP1A2CYP2C9P2RX7HTTADORA3 | |
| SCHEMBL16029005 | 0.76 | RXRA (0.35) | CYP1A2CYP2C9MAPTPOLB | |
| SCHEMBL4548449 | 0.76 | NOTUM (0.64) | MAPTSMN1; SMN2TP53POLBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6927230-B2 | Triazole derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2005-08-09 | — | — | US | disclosed |
| EP-1442026-A1 | TRIAZOLE DERIVATIVES AS CYCLOOXYGENASE (COX) INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-08-04 | — | — | EP | disclosed |
| WO-2004060367-A1 | IMIDAZOLE AND TRIAZOLE DERIVATIVES USEFUL AS SELECTIVE COX-1 INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-07-22 | — | — | WO | disclosed |
| US-20030191155-A1 | Triazole derivatives | ASTELLAS PHARMA INC. (JP) | 2003-10-09 | — | — | US | disclosed |
| WO-2003040110-A1 | TRIAZOLE DERIVATIVES AS CYCLOOXYGENASE (COX) INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-05-15 | — | — | WO | disclosed |
| US-4931083-A | Plant growth regulating triazoles | ELI LILLY AND COMPANY (US) | 1990-06-05 | — | — | US | disclosed |
| EP-0227284-A1 | Plant Growth regulating triazoles | ELI LILLY AND COMPANY (US) | 1987-07-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030191155-A1 | Triazole derivatives | CBR1, CBR3, CYP1B1 | CYP1A2 30/4885CYP2C9 83/4885P2RX7 2593/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.